Compile Data Set for Download or QSAR
Report error Found 190 Enz. Inhib. hit(s) with all data for entry = 233
TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244193(n-(3,4-dichlorobenzyl)-5,5-dimethyl-2-((tetrahydro...)
Affinity DataIC50: 1nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244250(n-((r)-1-(3-chlorophenyl)ethyl)-5-methyl-2-((tetra...)
Affinity DataIC50: 1.54nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243225((r)-n-(1-(3-chlorophenyl)ethyl)-5,5-dimethyl-2-((t...)
Affinity DataIC50: 2nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244182((r)-n-(1-(3-fluoro-5-(methylsulfonyl)phenyl)ethyl)...)
Affinity DataIC50: 2nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243205((s)-n-(1-(3-chlorophenyl)-2-hydroxyethyl)-5,5-dime...)
Affinity DataIC50: 4nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243224(n-(3-chlorobenzyl)-5,5-dimethyl-2-((tetrahydro-2h-...)
Affinity DataIC50: 6nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244176(n-(3-chloro-5-(methylsulfonyl)benzyl)-5,5-dimethyl...)
Affinity DataIC50: 6nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244191(n-(4-chloro-3-fluorobenzyl)-5,5-dimethyl-2-((tetra...)
Affinity DataIC50: 6nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244184((s)-n-(2-hydroxy-1-(3-(methylsulfonyl)phenyl)ethyl...)
Affinity DataIC50: 7nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244190(n-(4-bromobenzyl)-5,5-dimethyl-2-((tetrahydro-2h-p...)
Affinity DataIC50: 7nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243216(n-(3-chloro-5-fluorobenzyl)-5,5-dimethyl-2-((tetra...)
Affinity DataIC50: 8nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244195((s)-n-(1-(3-fluorophenyl)-2-hydroxyethyl)-5,5-dime...)
Affinity DataIC50: 9nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244198((r)-5,5-dimethyl-n-(1-(3-(methylsulfonyl)phenyl)et...)
Affinity DataIC50: 9nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243231(n-(4-chlorobenzyl)-5,5-dimethyl-2-((tetrahydro-2h-...)
Affinity DataIC50: 10nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244188(5,5-dimethyl-2-((tetrahydro-2h-pyran-4-yl)amino)-n...)
Affinity DataIC50: 10nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244161(n-(3-carbamoylbenzyl)-5,5-dimethyl-2-((tetrahydro-...)
Affinity DataIC50: 11nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244199(5,5-dimethyl-2-((tetrahydro-2h-pyran-4-yl)amino)-n...)
Affinity DataIC50: 11nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244200(5,5-dimethyl-n-(4-phenoxybenzyl)-2-((tetrahydro-2h...)
Affinity DataIC50: 11nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244167(n-(1-(2-fluorobenzyl)-1h-pyrazol-4-yl)-2'-((te...)
Affinity DataIC50: 12nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243244((r)-n-(1-((2-fluorophenyl)sulfonyl)piperidin-3-yl)...)
Affinity DataIC50: 13nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244004((s)-n-(2-hydroxy-1-phenylethyl)-2'-((tetrahydr...)
Affinity DataIC50: 13nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243204((s)-n-(2-hydroxy-1-phenylethyl)-5,5-dimethyl-2-((t...)
Affinity DataIC50: 14nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243226((r)-5,5-dimethyl-n-(1-phenylethyl)-2-((tetrahydro-...)
Affinity DataIC50: 14nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243235((s)-n-(2-amino-1-phenylethyl)-5,5-dimethyl-2-((tet...)
Affinity DataIC50: 14nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244207((r)-n-(1-(2-fluorobenzyl)pyrrolidin-3-yl)-5,5-dime...)
Affinity DataIC50: 14nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243223(n-(3-fluorobenzyl)-5,5-dimethyl-2-((tetrahydro-2h-...)
Affinity DataIC50: 16nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244178(n-(3-(ethylsulfonyl)benzyl)-5,5-dimethyl-2-((tetra...)
Affinity DataIC50: 16nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244194((s)-n-(2-hydroxy-1-(m-tolyl)ethyl)-5,5-dimethyl-2-...)
Affinity DataIC50: 16nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243239(5,5-dimethyl-n-(1-phenylcyclopropyl)-2-((tetrahydr...)
Affinity DataIC50: 17nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243207(5,5-dimethyl-n-(3-(methylsulfonyl)benzyl)-2-((tetr...)
Affinity DataIC50: 18nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244204(5,5-dimethyl-2-((tetrahydro-2h-pyran-4-yl)amino)-n...)
Affinity DataIC50: 19nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243222(n-(3,5-difluorobenzyl)-5,5-dimethyl-2-((tetrahydro...)
Affinity DataIC50: 21nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244196(5,5-dimethyl-n-(4-methylbenzyl)-2-((tetrahydro-2h-...)
Affinity DataIC50: 21nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244203((r)-n-(1-(4-cyanophenyl)ethyl)-5,5-dimethyl-2-((te...)
Affinity DataIC50: 21nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243227(n-(4-fluorobenzyl)-5,5-dimethyl-2-((tetrahydro-2h-...)
Affinity DataIC50: 22nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244005(n-(4-chlorobenzyl)-5-ethyl-5-methyl-2-((tetrahydro...)
Affinity DataIC50: 22nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244009((r)-5-ethyl-n-((s)-2-hydroxy-1-phenylethyl)-5-meth...)
Affinity DataIC50: 22nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244107((s)-2-(cyclohexylamino)-n-(2-hydroxy-1-phenylethyl...)
Affinity DataIC50: 22nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243212(5,5-dimethyl-n-((1r)-2-phenylcyclopropyl)-2-((tetr...)
Affinity DataIC50: 23nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244185((r)-n-(1-((3-chlorophenyl)sulfonyl)piperidin-3-yl)...)
Affinity DataIC50: 23nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243245((r)-5,5-dimethyl-n-(1-(phenylsulfonyl)piperidin-3-...)
Affinity DataIC50: 27nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243990((r)-methyl 3-((6-(((s)-2-hydroxy-1-phenylethyl)car...)
Affinity DataIC50: 30nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243248(n-benzyl-5,5-dimethyl-2-((tetrahydro-2h-pyran-4-yl...)
Affinity DataIC50: 31nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM243249(n-(cyclohexylmethyl)-5,5-dimethyl-2-((tetrahydro-2...)
Affinity DataIC50: 31nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244003(n-(4-chlorobenzyl)-2'-((tetrahydro-2h-pyran-4-...)
Affinity DataIC50: 31nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244206((r)-5,5-dimethyl-n-(1-(4-(methylsulfonyl)phenyl)et...)
Affinity DataIC50: 32nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244172(n-(1-(3-chlorobenzyl)-5-(methylcarbamoyl)piperidin...)
Affinity DataIC50: 37nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244189(n-(4-cyanobenzyl)-5,5-dimethyl-2-((tetrahydro-2h-p...)
Affinity DataIC50: 38nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244202(n-(3-cyanobenzyl)-5,5-dimethyl-2-((tetrahydro-2h-p...)
Affinity DataIC50: 38nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Novartis

US Patent
LigandPNGBDBM244173(n-(1-(2-fluorobenzyl)-1h-pyrazol-4-yl)-5,5-dimethy...)
Affinity DataIC50: 39nMpH: 7.5Assay Description:Compound potency against activated ERK2 was determined using a kinase assay that measures ERK2-catalyzed phosphorylation of biotinylated ERKtide pept...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 190 total ) | Next | Last >>
Jump to: